(S)-SNAP 5114 - CAS 157604-55-2
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C30H35NO6
Molecular Weight:
505.61
COA:
Inquire
Targets:
GABA Receptor
Description:
(S)-SNAP 5114 is a GABA transport inhibitor, displaying selectivity for GAT-3 and GAT-2 (IC50 = 5, 21 and 388 μM for hGAT-3, rGAT-2 and hGAT-1, respectively). (S)-SNAP 5114 was shown to increase thalamic GABA levels, and acts as an anticonvulsant following systemic administration in vivo.
Brife Description:
GABA transport inhibitor
Purity:
≥98% by HPLC
Synonyms:
SNAP-5114; SNAP 5114; SNAP5114; (S)-SNAP 5114; 1-[2-[tris(4-methoxyphenyl)methoxy]ethyl]-(S)-3-piperidinecarboxylic acid; (3S)-1-[2-[tris(4-methoxyphenyl)methoxy]ethyl]piperidine-3-carboxylic acid
MSDS:
Inquire
Application:
anticonvulsant
InChIKey:
VDLDUZLDZBVOAS-QFIPXVFZSA-N
InChI:
InChI=1S/C30H35NO6/c1-34-26-12-6-23(7-13-26)30(24-8-14-27(35-2)15-9-24,25-10-16-28(36-3)17-11-25)37-20-19-31-18-4-5-22(21-31)29(32)33/h6-17,22H,4-5,18-21H2,1-3H3,(H,32,33)/t22-/m0/s1
Canonical SMILES:
COC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC)(C3=CC=C(C=C3)OC)OCCN4CCCC(C4)C(=O)O
1.Inhibition of GABA transporters fails to afford significant protection following focal cerebral ischemia.
Lie ME;Gowing EK;Clausen RP;Wellendorph P;Clarkson AN J Cereb Blood Flow Metab. 2018 Jan;38(1):166-173. doi: 10.1177/0271678X17743669. Epub 2017 Nov 17.
Brain ischemia triggers excitotoxicity and cell death, yet no neuroprotective drugs have made it to the clinic. While enhancing GABAergic signaling to counterbalance excitotoxicity has shown promise in animal models, clinical studies have failed. Blockade of GABA transporters (GATs) offers an indirect approach to increase GABA inhibition to lower the excitation threshold of neurons. Among the GATs, GAT1 is known to promote neuroprotection, while the protective role of the extrasynaptic transporters GAT3 and BGT1 is elusive. A focal lesion was induced in the motor cortex in two to four-month-old C57BL/6 J male mice by photothrombosis. The GAT1 inhibitor, tiagabine (1 and 10 mg/kg), the GAT2/3 inhibitor, ( S)-SNAP-5114 (5 and 30 mg/kg) and the GAT1/BGT1 inhibitor, EF-1502 (1 and 10 mg/kg) were given i.p. 1 and 6 h post-stroke to assess their impact on infarct volume and motor performance seven days post-stroke. One mg/kg tiagabine improved motor performance, while 10 mg/kg tiagabine, ( S)-SNAP-5114 and EF-1502 had no effect. None of the compounds affected infarct volume. Interestingly, treatment with tiagabine induced seizures and ( S)-SNAP-5114 led to increased mortality. Although we show that tiagabine can promote protection, our findings indicate that caution should be had when using GAT1 and GAT3 inhibitors for conditions of brain ischemia.
2.New highly potent GABA uptake inhibitors selective for GAT-1 and GAT-3 derived from (R)- and (S)-proline and homologous pyrrolidine-2-alkanoic acids.
Fülep GH;Hoesl CE;Höfner G;Wanner KT Eur J Med Chem. 2006 Jul;41(7):809-24.
We synthesized proline and pyrrolidine-2-alkanoic acid derivatives in their enantiomerically pure form and evaluated them for their affinity to the GABA transport proteins GAT-1 and GAT-3. Among the compounds presented herein, (R)-pyrrolidine-2-acetic acid (R)-4d substituted with a 2-[tris(4-methoxyphenyl)methoxy]ethyl residue at the nitrogen atom showed the highest affinity at GAT-3 (IC(50) = 3.1 microM) comparable with the well-known GAT-3 blocker (S)-SNAP-5114. Compound (R)-4d displayed excellent subtype selectivity for GAT-3 (GAT-3:GAT-1 = 20:1). (S)-2-pyrrolidineacetic acid derivatives (S)-4b provided with a 4,4-diphenylbut-3-en-1-yl moiety and (S)-4c substituted with a 4,4-[di(3-methylthiophen-2-yl)]phenylbut-3-en-1-yl residue at the nitrogen atom exhibited IC(50) values of 0.396 microM and 0.343 microM at the GAT-1 protein, respectively.
3.Comparison of the uptake of 5-aminolevulinic acid and its methyl ester in keratinocytes and skin.
Schulten R;Novak B;Schmitz B;Lübbert H Naunyn Schmiedebergs Arch Pharmacol. 2012 Oct;385(10):969-79. doi: 10.1007/s00210-012-0777-4. Epub 2012 Jul 17.
Photodynamic therapy is widely used in the treatment of superficial skin cancers. 5-Aminolevulinic acid (ALA) and its methylated form, methyl-ALA (MAL), are frequently used as precursors to photosensitizing substances. Nevertheless, the mechanism of the uptake of ALA and MAL in keratinocytes and of their skin penetration is still controversial. Since both compounds are not sufficiently lipophilic to penetrate through lipid membranes, they must employ specific uptake systems which may vary between different cell types. Here, we studied ALA and MAL uptake in keratinocyte cell lines originating from healthy cells (CCD 1106 KERTr cells) or keratinocyte tumors (A431 cells). ALA uptake resulted in faster protoporphyrin IX (PpIX) production than MAL uptake. A pharmacological characterization of the uptake systems revealed that PpIX formation was most efficiently reduced with GABA transporter (GAT) substrates. GABA, β-alanine, and (S)-SNAP-5114 reduced ALA uptake and, to a lesser extent, MAL uptake in the cell lines. The pharmacology of these compounds indicates that ALA and MAL are taken up by normal and pathological keratinocytes via GAT-3. Furthermore, the amino acids arginine, cysteine, and histidine also inhibited the uptake of ALA, and even more so MAL, suggestive of an additional involvement of amino acid transporters.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related GABA Receptor Products


CAS 160296-13-9 SB 205384

SB 205384
(CAS: 160296-13-9)

SB 205384 is a GABAA receptor modulator. SB 205384 potentiates α6, α3 and α5-subunit-containing receptors (EC50 = 280, 695 and 730 nM, respectively). It exhibit...

CAS 64603-91-4 Gaboxadol

Gaboxadol
(CAS: 64603-91-4)

Gaboxadol is a GABA agonist. It was a non-opioid analgesic and a novel type of hypnotic. It was first synthesized in 1977 by the Danish chemist Povl Krogsgaard-...

CAS 38090-53-8 TACA

TACA
(CAS: 38090-53-8)

TACA, the trans-isomer of CACA, is a potent GABAA and GABAC agonist, GABA uptake inhibitor and substrate for GABA-T. It also acts as a GABAA-ρ agonist.

CAS 951654-29-8 2-{3-[5-(2-Hydroxypropan-2-yl)-1H-1,3-benzodiazol-1-yl]phenyl}benzamide

2-{3-[5-(2-Hydroxypropan-2-yl)-1H-1,3-be
(CAS: 951654-29-8)

A GABAA receptor modulator that effects against anxiety.

CAS 1216792-30-1 ZK 93426 hydrochloride

ZK 93426 hydrochloride
(CAS: 1216792-30-1)

ZK 93426 hydrochloride is a potent, selective and competitive benzodiazepine receptor antagonist (IC50 = 0.4 and 0.7 nM for inhibition of [3H]-flunitrazepam bin...

CAS 142720-24-9 FGIN-1-27

FGIN-1-27
(CAS: 142720-24-9)

FGIN-1-27 is a high affinity agonist of mitochondrial benzodiazepine receptors (PBR) binding to benzodiazepine receptors on mitochondrial membranes. FGIN-1-27 i...

CAS 134516-99-7 U 90042

U 90042
(CAS: 134516-99-7)

U 90042 is a GABAA receptor ligand binding to three receptor subtypes: α1β2γ2, α3β2γ2 and α6β2γ2 (Ki = 7.8, 9.5 and 11.0 nM, respectively). U 90042 potentiates ...

CAS 110283-66-4 CI 966 hydrochloride

CI 966 hydrochloride
(CAS: 110283-66-4)

The hydrochloride salt form of CI 966, which is an inhibitor of the GABA transporter and could be used as anticonvulsive as well as neuroprotective agent.

Chemical Structure

CAS 157604-55-2 (S)-SNAP 5114

Quick Inquiry

Verification code

Featured Items